Additional evidence of the metabolic consequences of proteasome inhibitors is also provided by their interaction with mTOR, an integrator of environmental signals to regulate protein synthesis, autophagy, cell proliferation, growth and survival that plays a key role in MM and other cancers (55, 56). This evidence concerns the gene MTOR and Miyoshi myopathy.